A stapled viral peptide blocks HSV-2 from infecting human cervical cells

Area of Science:

• Virology
• Antiviral drug development

Background:

• Herpes Simplex Virus-2 (HSV-2) is a primary cause of genital herpes.
• Current prevention and treatment options for HSV-2 are limited, with growing concerns about drug resistance to acyclovir.
• There is a critical need for novel therapeutic strategies against HSV-2 infection.

Purpose of the Study:

• To evaluate the efficacy of the stapled peptide SPep7B against HSV-2 replication and infection.
• To assess the safety and pharmacokinetic properties of SPep7B for potential topical application.

Main Methods:

• In vitro assays to determine SPep7B's antiviral activity against HSV-2.
• Three-dimensional (3D) human vaginal cell models to simulate HSV-2 infection.
• Cytotoxicity, mutagenicity, and metabolic stability assays for SPep7B.
• Epithelial tissue penetration studies.

Main Results:

• SPep7B demonstrated the ability to target HSV-2 replication in vitro.
• SPep7B effectively blocked HSV-2 infection in 3D human vaginal cell models.
• The peptide exhibited low cytotoxicity, was non-mutagenic, showed high metabolic stability in plasma, and could penetrate epithelial tissue.

Conclusions:

• SPep7B shows significant potential as a topical antiviral agent for treating HSV-2 genital herpes.
• The peptide's favorable safety and stability profile supports its further development.
• SPep7B represents a promising new therapeutic candidate for managing HSV-2 infections.